ReviewHeart failure reviews2025
Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.
Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly 50% of all heart failure cases and remains a significant clinical challenge. It is characterized by a complex pathophysiology involving multiple comorbidities and overlapping symptoms between heart failure and these comorbid conditions (e.g., obesity). Due to this complexity, several pharmacological treatments that have proven effective in heart failure with reduced ejection fraction (HFrEF) have failed to improve outcomes in HFpEF. More recently, mineralocorticoid receptor antagonists, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential benefits in symptom relief and prognosis improvement in patients with HFpEF. In recent years, artificial intelligence has demonstrated the ability to identify distinct HFpEF phenotypes associated with varying risks of cardiovascular outcomes. In this context, clinicians should be able to recognize patients who require closer monitoring and more intensive follow-up. Given the frequent scarcity of healthcare resources, which can negatively impact patient management, remote monitoring may serve as a valuable tool in the follow-up of HFpEF patients. This review aims to describe and highlight these key aspects of HFpEF, with a particular focus on recent evidence and emerging strategies in disease management.
Indexed as
Identifiers
41320694What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.